Search
Lysergic acid diethylamide
go.drugbank.com/drugs/DB04829IllicitInvestigationalDebate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a mani...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesBiricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitorsNilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigationalNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered si...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesClevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTelmapitant
go.drugbank.com/drugs/DB20768ExperimentalThe usage of the INN stem '-pitant' in the name indicates that Telmapitant is a neurokinin NK1 (substance P) receptor antagonist. Telmapitant has a monoisotopic molecular weight of 515.16 Da.
Taltobulin
go.drugbank.com/drugs/DB20832ExperimentalTaltobulin is a small molecule drug. Taltobulin has a monoisotopic molecular weight of 473.33 Da.
Categories: P-glycoprotein substratesTabimorelin
go.drugbank.com/drugs/DB20892ExperimentalTabimorelin is a small molecule drug. The usage of the INN stem '-relin' in the name indicates that Tabimorelin is a pituitary hormone-release stimulating peptide. Tabimorelin has a monoisotopic molecular weight of 528.31 Da.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors